Ahmedabad: Zydus Lifesciences Limited has announced that it has entered into a definitive agreement with Agenus Inc. to ...

Agenus, which has been going through a reorganization after the FDA put the brakes on the biotech's regulatory plan for its ...

CVS Caremark will add Zydus' Zituvio™ and combination products to its template ... extended-release tablets. These three NDAs of Sitagliptin (base) and combination franchise have been approved ...

Zydus Receives Final Approval From The USFDA For Lacosamide Tablets The drug will be manufactured ... The medicine can be used either alone or in combination with other antihypertensive agents ...

Zituvimet and Zituvimet XR tablets used in treatment of diabetes to the latter's template formulary. CVS Caremark will add ...

The Subject Expert Committee (SEC) under the Central Drugs Standard Control Organisation (CDSCO) has directed Zydus ...

Zydus Lifesciences has received tentative approval from the US Food and Drug Administration to market Rifaximin Tablets in ...

(Image Credits: Pixabay) Zydus Lifesciences Limited on Tuesday announced its focus on the development of a combination vaccine against shigellosis and typhoid. This combination vaccine, being ...

Zituvimet and Zituvimet XR tablets to its template formulary. CVS Caremark will add Zydus’ Zituvio and combination products to its template formulary starting January 1, 2025. TipRanks is the ...

The project is expected to get underway in March 2025. Zydus Lifesciences on Tuesday said it will undertake development of a combination vaccine against shigellosis and typhoid. The company ...

tablets to its template formulary. CVS Caremark will add Zydus' Zituvio™ and combination products to its template formulary starting January 1, 2025. Zituvio and combination products include ...

Zydus will carry out early-stage development, animal immunogenicity studies and regulatory preclinical toxicology studies for this combination vaccine. The project is expected to get underway in ...